Background & Aims: GSK2336805 is a HCV NS5A inhibitor for chronic hepatitis C (CHC). In a prior Phase I study, GSK2336805 was well tolerated and had an antiviral and pharmacokinetic profile suitable for once-daily administration. This 28-day, double-blind, randomized, placebo-controlled study evaluated once daily GSK2336805 60 mg alone or in combination with peginterferon alfa-2a (180 μg per week) and ribavirin (1000-1200 mg daily) (PEG/RIBA) in treatment-naive genotype 1 CHC subjects.
Methods: Five centres enrolled 16 subjects in the USA and Puerto Rico who received GSK2336805 + PEG/RIBA or placebo + PEG/RIBA.
Results: Following a single monotherapy dose of GSK2336805 on day 1, median reduction from baseline in HCV RNA was -2.96 log10 (N = 11) vs. -0.13 log10 (N = 4) for placebo. With the addition of PEG/RIBA on day 2, subjects receiving GSK2336805 exhibited greater decreases in viral load over the 28-day treatment period as compared with placebo. At day 28, median reduction from baseline was -4.86 log10 (N = 9) in the GSK2336805 + PEG/RIBA group as compared with -1.98 log10 (N = 4) in the placebo + PEG/RIBA group. At day 28, rapid virological response (RVR) occurred in 8/11 (73%) of the GSK2336805 + PEG/RIBA subjects as compared with 1/4 (25%) of the placebo + PEG/RIBA subjects. Adverse events were consistent with those reported in clinical trials of peginterferon and ribavirin, and no unique adverse events appeared to be associated with GSK2336805.
Conclusions: GSK2336805 is a potent NS5A inhibitor that showed a substantial antiviral effect as a monotherapy and in combination with peginterferon and ribavirin. ClinicalTrials.gov Identifier: NCT01439373.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/liv.12334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients.
World J Hepatol
October 2024
Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Article Synopsis
- Hepatitis B virus (HBV) infection is linked to a high incidence of hepatocellular carcinoma (HCC), especially in China, where around 92.05% of liver cancer patients are infected with HBV.
- The immune environment around tumors (TME) changes due to HBV, allowing cancer cells to escape immune detection, often with the help of proteins like CTLA-4 and PD-1/PD-L1 that suppress T cell activity.
- Recent advancements in immunotherapy, including treatments with interferons and PD-1/L1 inhibitors, show promise for HBV-related HCC patients, raising questions about their efficacy for Chinese patients with distinct disease characteristics.
Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis.
BMC Infect Dis
October 2024
Department of infectious Diseases, The Second Affiliated Hospital and Yuying Children's Hospital, of Wenzhou Medical University, Wenzhou, China.
Background: The best antiviral treatment for chronic hepatitis B (CHB) poses a complex challenge. The treatment effect of the combination of nucleoside analogues (NAs) and pegylated interferon alpha (PegIFN) was still in debate.
Methods: We studied patients treated with NAs and PegIFN-2b at our institution from November 2019 to January 2022.
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study.
Lancet Gastroenterol Hepatol
December 2024
Department of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Article Synopsis
- Chronic hepatitis B virus (HBV) is a significant global health concern, with existing treatments yielding low rates of HBsAg seroclearance; VIR-2218 (elebsiran) is being studied for its potential to reduce HBsAg levels.
- This phase 2 open-label study involved participants aged 18-65 from various countries who had chronic HBV but no cirrhosis, assessing the safety and effectiveness of VIR-2218 alone and in combination with pegylated interferon-alpha-2a.
- The study aimed to measure adverse events and clinical outcomes, including the reduction of HBsAg and long-term seroclearance rates among those receiving different treatment regimens over a period ranging from
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Treating HCV Genotypes 1 and 4 in Patients with Advanced Chronic Kidney Disease.
J Pharm Bioallied Sci
July 2024
Department of Medicine, Division of Gastroenterology and Hepatology, College of Medicine, Qassim University, Buraydah, Saudi Arabia.
This study assessed the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) combined with dasabuvir (DSV) for treating hepatitis C genotype 4 (GT4) and genotype 1 (GT1) in patients with stage 4 or 5 chronic kidney disease (CKD). Among 88 patients, including treatment-naïve and Peginterferon/Ribavirin (RBV)-experienced, treated with OBV/PTV/r±RBV (dosed between 200 mg per week to daily) and additional DSV for GT1, 94.3% achieved sustained virologic response at 12 weeks (SVR12), demonstrating high efficacy.
View Article and Find Full Text PDFCXCR7 genetic variant predicts treatment response of pegylated-interferon α in HBeAg-positive chronic hepatitis B patients.
Antiviral Res
November 2024
State Key Laboratory of Organ Failure Research, MOE Key Laboratory of Infectious Diseases Research in South China, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China; The Key Laboratory of Molecular Pathology (Hepatic Diseases) of Guangxi, Department of Pathology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China. Electronic address:
Article Synopsis
- - The study investigates the role of CXC chemokine receptor 7 (CXCR7) in patients with chronic hepatitis B (CHB) undergoing pegylated interferon-alpha (PegIFNα) therapy, specifically looking at how CXCR7 can predict treatment response.
- - Researchers analyzed data from 945 Chinese CHB patients who received PegIFNα treatment and found that a specific SNP (rs2952665) within the CXCR7 gene was significantly linked to successful treatment outcomes.
- - The study concludes that CXCR7_rs2952665, alongside a polygenic score combining it with other known SNPs, serves as a strong predictor for treatment efficiency in HBeAg-positive CHB patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!